Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 976-984

  Anagnostou, Valsamo K ^a   Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMS 936559; BMS 986016; CARBOPLATIN; CISPLATIN; COBIMETINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DURVALUMAB; ERLOTINIB; GEFITINIB; GEMCITABINE; IPILIMUMAB; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PLACEBO; PLATINUM COMPLEX; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR; TECEMOTIDE; TG 4010; TICILIMUMAB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CANCER VACCINE;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CHEMORADIOTHERAPY; COLITIS; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPOPHYSITIS; IMMUNOSURVEILLANCE; LOW DRUG DOSE; LUNG TOXICITY; NON SMALL CELL LUNG CANCER; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PROCEDURES; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84929456860     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1187     Document Type: Article

References (75)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Pao W, Girard N. New driver mutations in non-small cell lung cancer. Lancet Oncol 2011; 12: 175-80.
3. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2012; 10: 1236-71.
4. Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 2012; 12: 923-37.
5. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168: 4272-6.
6. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013; 1284: 1-5.
7. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
8. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
9. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Ann Rev Immunol 2011; 29: 235-71.
10. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-46.
11. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1005.
12. Radoja S, Rao TD, Hillman D, Frey AB. Mice bearing late-stage tumors have normal functional systemic T-cell responses in vitro and in vivo. J Immunol 2000; 164: 2619-28.
13. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
14. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
15. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-77.
16. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229: 12-26.
17. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T-cell function. Science 2008; 322: 271-5.
18. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
19. Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, et al. Cancer-induced immunosuppression: IL18-elicited immunoablative NK cells. Cancer Res 2012; 72: 2757-67.
20. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-9.
21. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T-cell activation. Nat Immunol 2001; 2: 261-8.
22. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-29.
23. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13: 84-8.
24. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008; 105: 20852-7.
25. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expressioninhuman melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.
26. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-6.
27. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99: 12293-7.
28. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30: 2046-54.
29. Zatloukal P, Heo DS, Park K, Kang J, Butts C, Bradford S, et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care following first line platinum-based therapy in patients with advanced non-small cell lung cancer. J Clin Oncol 27: 15s, 2009 (suppl; abstr 8071).
30. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-75.
31. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
32. Brahmer JR, Horn L, Antonia S, Spigel DR, Gandhi L, Sequist LV, et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 30, 2012 (suppl; abstr 7509).
33. Brahmer JR, Horn L, Antonia SJ, Spigel DR, Gandhi L, Sequist LV, et al. Survival and long-term follow-up of the phase I trial of nivolumab (anti-PD-1; BMS-936588; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol 31, 2013 (suppl; abstr 8030).
34. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107: 4275-80.
35. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
36. Antonia SJ, Gettinger SN, Chow LQM, Juergens RA, Borghaei H, Shen Y, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol 32: 5s, 2014 (suppl; abstr 8023).
37. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, Juergens R, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 32: 5s, 2014 (suppl; abstr 8024).
38. Antonia SJ, Brahmer JR, Gettinger SN, Chow LQM, Juergens RA, Shepherd FA, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 32: 5s, 2014 (suppl; abstr 8113).
39. Garon EB, Leighl NB, Rizvi NA, Blumenschein GR, Balmanoukian AS, Eder JP, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 32: 5s, 2014 (suppl; abstr 8020).
40. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
41. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7.
42. Khleif S, Lutzky J, Segal NH, Antonia S, Blake-Haskins A, Stewart R, et al. MEDI4736, an anti-PD-L1 antibody with engineered Fc domain: preclinical evaluation and early clinical results from a phase I study in patients with advanced solid tumors [abstract]. In: Proceedings of the European Cancer Congress; 2013 Sep 27-Oct 1; Amsterdam, the Netherlands; 2013. Abstract nr 802.
43. Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li X, et al. Clinical activityand biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol 32: 5s, 2014 (suppl; abstr 8021).
44. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-20.
45. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2012; 18: 336-41.
46. Gandhi L, Balmanoukian AS, Hui R, Hamid O, Rizvi NA, Leighl NB, et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr CT105.
47. Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer: additional analyses from aclinical study of the engineered antibody MPDL3280A (anti-PDL1) [abstract]. In: Proceedings of the European Cancer Congress; 2013 Sep 27-Oct 1; Amsterdam, the Netherlands; 2013. Abstract nr 3408.
48. Garon EB, Gandhi L, Rizvi N, Hui R, Balmanoukian AS, Patnaik A, et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol 2014; 25:v1-v41.
49. Hellmann MD, Creelan BC, Woo K, Sima CS, Iams WT, Antonia SJ, et al. Smoking history and response to nivolumab in patients with advanced NSCLC. Ann Oncol 2014; 25:iv426-v70.
50. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-58.
51. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-99.
52. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5: 5241.
53. Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, et al. Association of epithelia-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: implications for immunotherapy biomarkers. J Clin Oncol 32: 5s, 2014 (suppl; abstr 3018).
54. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014; 11: 24-37.
55. Cuppens K, Vansteenkiste J. Vaccination therapy for non-small cell lung cancer. Curr Opin Oncol 2014; 26: 165-70.
56. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
57. Samuel J, Budzynski WA, Reddish MA, Ding L, Zimmermann GL, Krantz MJ, et al. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer 1998; 75: 295-302.
58. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 59-68.
59. Jang SJ, Soria JC, Wang L, Hassan KA, Morice RC, Walsh GL, et al. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 2001; 61: 7959-63.
60. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small cell lung cancer: phase II randomized study results. J Clin Oncol 2013; 31: 2396-403.
61. Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013; 31: 2388-95.
62. Update on phase III clinical trial of investigational MAGE-A3 antigenspecific cancer immunotherapeutic in non-small cell lung cancer. Eur Pharm Rev 2014 April 2 [cited 2014 Dec 17]. Available from: http://www.europeanpharmaceuticalreview.com/24811/news/industry-news/update-phase-iii-clinical-trial-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-non-small-cell-lung-cancer/
63. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011; 12: 1125-33.
64. Gonzalez G, Crombet T, Catala M, Mirabal V, Hernandez JC, Gonzalez Y, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998; 9: 431-5.
65. Garcia B, Neninger E, de la Torre A, Leonard I, Martinez R, Viada C, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008; 14: 840-6.
66. Macias A, Alfonso S, Santiesteban E, Viada C, Mendoza I, Guerra PP. Active specific immunotherapy with racotumomab in the treatment of advanced non-small cell cancer. Ann Oncol 2012; 23:ix400-ix46.
67. Giaccone G, Bazhenova L, Nemunaitis J. A phase III study of belagenpu-matucel-L therapeutic tumor cell vaccine for non-small cell lung cancer [abstract]. In: Proceedings of the European Cancer Congress; 2013 Sep 27-Oct 1; Amsterdam, the Netherlands; 2013. Abstract nr 7081.
68. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2014; 2: 831-8.
69. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124: 687-95.
70. Sharabi A, Nirschl C, Ceccato T, Nirschl T, Francica B, Alme A, et al. Radiotherapy combined with anti-PD-1 checkpoint blockade immunotherapy: a promising future direction [abstract]. In: Proceedings of the 56th Annual Meeting of the American Society for Radiation Oncology; 2014 Sept 14-17; San Francisco, CA. Fairfax (VA): ASTRO; 2014. Abstract nr PL-01.
71. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013; 1: 365-72.
72. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355-63.
73. Ganesan AP, Johansson M, Ruffell B, Yagui-Beltran A, Lau J, Jablons DM, et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T-cell responses to lung adenocarcinoma. J Immunol 2013; 191: 2009-17.
74. Buchan SL, Manzo T, Flutter B, Rogel A, Edwards N, Zhang L, et al. OX40-and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J Immunol 2015; 194: 125-33.
75. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 2014; 92: 475-80.